论文部分内容阅读
72例T2DM患者随机分为试验组36例,口服达美康缓释片,每日30~60mg,每日1次;对照组36例,口服格列齐特片,每日80~160mg,每日2次口服,疗程12周。结果:两组均可有效降低空腹血糖(FBG)、餐后2小时血糖(2hPG)和糖化血红蛋白(HbA1c)水平(P<0.05),两组比较差异无显著性(P>0.05)。结论:达美康缓释片与普通剂型的疗效与安全性相似。
72 patients with T2DM were randomly divided into experimental group of 36 cases, oral demecon sustained-release tablets, daily 30 ~ 60mg, 1 day; control group of 36 patients, oral gliclazide tablets, daily 80 ~ 160mg, each Day 2 oral, treatment for 12 weeks. Results: Fasting plasma glucose (FBG), 2hPG and HbA1c were significantly decreased in both groups (P <0.05). There was no significant difference between the two groups (P> 0.05). Conclusion: The efficacy and safety of Deltamellil sustained-release tablets and ordinary dosage forms are similar.